
HealthMore in Health→
J&J Pulls Back Two Lymphoma CAR-T Programs as the Treatment Market Shifts
Johnson & Johnson is discontinuing two CAR-T therapy programs for B-cell lymphoma, pointing to an increasingly crowded treatment landscape shaped by recent approvals in cell therapy and antibody-based drugs.
Key Takeaways
- Johnson & Johnson is scrapping two CAR-T programs for B-cell lymphoma.
- The company cites an evolving market for the decision.
DE
DT Editorial Team··via endpoints.news